TRANSGENE

Aulos Bioscience announced the first patients dosed in a Phase I/II trial investigating avelumab, in combination with imneskibart and low-dose, subcutaneous aldesleukin, for non-small cell lung cancer. The trial follows a collaboration and supply agreement with Merck, evaluating the combination therapy for second-line treatment. Pre-clinical results showed strong anti-cancer activity, including complete tumour eradication.

The global cancer profiling market is projected to grow from $31.816 billion in 2024 to $59.049 billion by 2029, driven by rising cancer prevalence, biomarker use in tumor profiling, and demand for personalized medicine. Key developments include Guardant Health's tissue genomic profiling test and QIAGEN's NGS analysis tool for stomach cancer. North America leads in market share due to increased cancer research and precision treatment efforts.

Transgene presents TG4050 Phase I data at SITC 2024, showing 16 head and neck cancer patients remain disease-free post-treatment. Financial visibility confirmed into Q4 2025.

Transgene and NEC announced 24.1-month median follow-up data from the phase I trial of TG4050, an individualized immunotherapy for head and neck cancers, showing all 16 patients treated remain disease-free. TG4050, based on Transgene’s myvac platform and NEC’s AI, demonstrated strong immunogenicity with sustained immune responses and mild adverse events. A phase II part of the trial is currently enrolling patients.

Transgene and NEC announced 24.1-month median follow-up data from a Phase I trial of TG4050 in head and neck cancer treatment, showing 16 patients remain disease-free. TG4050, an individualized immunotherapy, demonstrated strong immunogenicity and sustained immune responses with mild to moderate adverse events. The trial has expanded to a Phase I/II trial.

24.1-month follow-up data from TG4050 trial shows all treated patients remain disease-free, with sustained immune responses. A Phase II part is now enrolling patients internationally.

Transgene partners with ProBioGen to enhance manufacturing of individualized cancer vaccines using ProBioGen's AGE1.CR.pIX® suspension cell line, aiming to improve scalability and efficiency for large-scale production.

Transgene and ProBioGen announce a license agreement for ProBioGen's AGE1.CR.pIX suspension cell line, aiming to enhance Transgene's individualized cancer vaccine program and myvac® platform through ProBioGen's production technology.

Dyno Therapeutics partners with Roche to develop AI-driven AAV gene therapy vectors for neurological diseases, with Roche paying $50m upfront and potential milestone payments exceeding $1bn.

The phase 2 trial of TG4001 plus avelumab did not improve PFS in HPV16-positive cervical or anogenital tumors, missing the primary end point. A subgroup analysis showed a positive trend favoring the combination in cervical cancer patients. The combination was well tolerated, and further analyses are planned.